×

CombiMatrix Launches Buccal Swab DNA Collection as Alternative to Blood Draws for Postnatal Genetic Testing

IRVINE, Calif., April 16, 2015 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based diagnostic services for prenatal, postnatal, and pre-implantation genetic testing today announced the availability of its new Buccal Swab DNA Collection system for the CombiSNP Array for Pediatric Analysis microarray test effective May 1. The collection system uses a cheek swab in lieu of a blood draw, which provides a more comfortable and convenient way to collect samples from neonates and pediatric patients.

"Because of our High Touch service-oriented business model, we are constantly looking for ways to improve our offering to physicians and their patients," said Mark McDonough, President and Chief Executive Officer of CombiMatrix. "The Buccal Swab DNA Collection system is particularly helpful to those physicians who do not have in-house phlebotomy services, and must send their patients to a phlebotomy center. Now, the patient's DNA can be collected in the physician's office without the need for a blood draw. The Buccal Swab DNA Collection system saves patients' time, and offers a painless alternative to a blood draw, which is particularly useful when samples need to be collected from neonatal and pediatric patients. We are excited about offering this option and believe that it will open up new testing avenues for office-based physicians who see patients that require microarray testing. This is largely an untapped market for us until now."

Sample collection is very easy to perform: simply swab both cheeks, cap the tube, and then invert it to mix the DNA with the special preservative solution. Samples are then sent to the Company's testing laboratory in Irvine, California, where the DNA is extracted and run on the same test platform as the blood samples.

About CombiMatrix Corporation

CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support for the highest quality of care – specializing in pre-implantation genetic screening, miscarriage analysis, prenatal and pediatric healthcare. CombiMatrix offers comprehensive testing services for the detection of abnormalities of genes at the DNA level beyond what can be identified through traditional technologies. The Company performs genetic testing utilizing microarray, FISH, PCR and G-Band chromosome analyses. Additional information about CombiMatrix is available at www.combimatrix.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations, speak only as of the date hereof and are subject to change. All statements, other than statements of historical fact included in this press release, are forward-looking statements. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "goal," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," "objective," similar expressions, and variations or negatives of these words. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include, but are not limited to: market acceptance of our buccal swab DNA collection system by physicians; our ability to successfully expand the base of our customers and strategic partners, add to the menu of our diagnostic tests in both of our primary markets, develop and introduce new tests and related reports, optimize the reimbursements received for our testing services, and increase operating margins by improving overall productivity and expanding sales volumes; our ability to successfully accelerate sales, steadily increase the size of our customer rosters; our ability to attract and retain a qualified sales force; rapid technological change in our markets; changes in demand for our future services; legislative, regulatory and competitive developments; general economic conditions; and various other factors. Further information on potential factors that could affect our financial results is included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law.

CONTACT: Company Contact: Mark McDonough President & CEO, CombiMatrix Corporation (949) 753-0624 Media Contact: David Schull or Lena Evans Russo Partners LLC (212) 845-4271 david.schull@russopartnersllc.com lena.evans@russopartnersllc.com Investor Contact: Robert Flamm, Ph.D. Russo Partners, LLC (212) 845-4226 robert.flamm@russopartnersllc.com

Source:CombiMatrix Corporation